PATENT 454313-3160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Jean-Christophe Francis AUDONNET et al.

Serial No.

09/677,672

Filed

October 2, 2000

For

ADJUVANT-CONTAINING DNA VACCINES

745 Fifth Avenue New York, New York 10151 Tel. (212) 588-0800

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Commissioner of Patents and Trademarks Washington, DC 20231, on January 31, 2001

William S. Frommer, Reg. No. 25,506

Name of Applicant, Assignee or Registered Representative

January 31, 2001

Date of Signature

### REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is a Request to correct the Filing Receipt issued in the above-interfied application, in order to correct the noted inadvertent error. A copy of the Filing Receipt with the requested correction noted thereon in red ink is enclosed.

It is believed that no fees are required for this correction. However, if any fees are required, or if any overpayment has been made, please charge Deposit Acct. No. 50-0320.

Respectfully submitted, FROMMER LAWRENCE & HAUG LLP Attorneys for Applicants

By:\_\_\_\_\_

William S. Frommer Reg. No. 25,506 Tel. (212) 588-0800

Enc. - Copy of Filing Receipt



## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/677,672 /	10/02/2000	/ 1645	710	454313- 3160 /	6	14	1

· William S Frommer Esq c/o Frommer Lawrence & Harps LP 745 Fifth Avenue · New York, NY 10151 FEB 0 5 2001

FILING RECEIPT

OCO 000000005684872\*

Date Mailed: 01/17/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jean-Christophe Francis Audonnet, Lyon, FRANCE; Jules Maarten Minke, Corbas, FRANCE;

**Continuing Data as Claimed by Applicant** 

THIS APPLICATION IS A CIP OF PCT/FR99/00666 03/22/1999

**Foreign Applications** 

FRANCE 98 04 409 04/03/1998 /

If Required, Foreign Filing License Granted 01/17/2001

Title

Adjuvant-containing vaccines

AUG-

**Preliminary Class** 

530

Data entry by: THOMAS, SHEILA

Team: OIPE

Date: 01/17/2001

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231







# UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

|--|

Bib Data Sheet			<del>-</del>							
SERIAL NUMBE 09/677,672	FILING DATE 10/02/2000 RULE _	<b>CLASS</b> 530	GROUP ART UI 1645	D(	ATTORNEY DOCKET NO. 454313-3160					
APPLICANTS  Jean-Christophe Francis Audonnet, Lyon, FRANCE;  Jules Maarten Minke, Corbas, FRANCE;										
** <b>CONTINUING DATA</b> ***********************************										
** FOREIGN APPLICATIONS ************************************										
IF REQUIRED, FOREIGN FILING LICENSE  GRANTED ** 01/17/2001 –										
Foreign Priority claimed 35 USC 119 (a-d) condi met Verified and Acknowledged	tions yes no Met aff	STATE OR COUNTRY FRANCE	.	TOTAL CLAIMS 14	INDEPENDENT CLAIMS 1					
ADDRESS  - William S Frommer Esq c/o Frommer Lawrence & Haug LLP 745 Fifth Avenue New York ,NY 10151										
TITLE										
Adjuvant-contain	ing DNA vaccines									
RECEIVED	FEES: Authority has been No to charge/o No for followir	1.16 I	All Fees  1.16 Fees (Filing)  1.17 Fees (Processing Ext. of time)  1.18 Fees (Issue)  Other  Credit							